CNBC TV18 | 18/05/2021 04:35 PM | Click to read full article
The Food and Drug Administration expanded emergency use authorisation of the Pfizer-BioNTech COVID-19 vaccine to include adolescents 12 to 15 years of age on May 10, 2021.
The Centres for Disease Control and Prevention followed with recommendations endorsing use in this age group after their advisory group meeting on May 12. Adolescents made high levels of antibody in response to the vaccine, and their immune response was just as strong as what has been seen in older teens and young adults 16-25 years of age. 2.